Clitocine induces apoptosis and enhances the lethality of ABT-737 in human colon cancer cells by disrupting the interaction of Mcl-1 and Bak

Cancer Letters

Volumn 355, Issue 2, 2014, Pages 253-263

  Sun, Jian guo ^a,b   Xiang, Jun ^a   Zeng, Xue li ^a   Li, Xia ^a   Wu, Ping ^a,b   Fung, Kwok Pui ^b   Liu, Fei yan ^a,b  

^a ZHEJIANG UNIVERSITY   (China)

^b CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

ABT 737; Apoptosis; Bak; Clitocine; Mcl 1

Indexed keywords

4 [4 (4' CHLORO 2 BIPHENYLYLMETHYL) 1 PIPERAZINYL] N [4 [3 DIMETHYLAMINO 1 (PHENYLTHIOMETHYL)PROPYLAMINO] 3 NITROBENZENESULFONYL]BENZAMIDE; ANTINEOPLASTIC AGENT; CLITOCINE; PROTEIN BAK; PROTEIN MCL 1; UNCLASSIFIED DRUG; ABT-737; BAK1 PROTEIN, HUMAN; BIPHENYL DERIVATIVE; MCL1 PROTEIN, HUMAN; NITROPHENOL; PIPERAZINE DERIVATIVE; PROTEIN BCL 2; PYRIMIDINE NUCLEOSIDE; SULFONAMIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; COLON CANCER; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG MECHANISM; DRUG POTENTIATION; DRUG SENSITIVITY; DRUG STRUCTURE; HUMAN; HUMAN CELL; MITOCHONDRIAL PERMEABILITY; MITOSIS INHIBITION; MONOTHERAPY; MOUSE; NONHUMAN; TUMOR XENOGRAFT; ANIMAL; CACO 2 CELL LINE; CELL MEMBRANE PERMEABILITY; COLONIC NEOPLASMS; DRUG EFFECTS; DRUG SCREENING; HCT116 CELL LINE; METABOLISM; MITOCHONDRION; NUDE MOUSE; PATHOLOGY; RANDOMIZATION; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; BCL-2 HOMOLOGOUS ANTAGONIST-KILLER PROTEIN; BIPHENYL COMPOUNDS; CACO-2 CELLS; CELL LINE, TUMOR; CELL MEMBRANE PERMEABILITY; COLONIC NEOPLASMS; HCT116 CELLS; HUMANS; MICE; MICE, NUDE; MITOCHONDRIA; MYELOID CELL LEUKEMIA SEQUENCE 1 PROTEIN; NITROPHENOLS; PIPERAZINES; PROTO-ONCOGENE PROTEINS C-BCL-2; PYRIMIDINE NUCLEOSIDES; RANDOM ALLOCATION; SULFONAMIDES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84908181239     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2014.09.024     Document Type: Article

References (49)

1. Danial N.N. BCL-2 family proteins: critical checkpoints of apoptotic cell death. Clin. Cancer Res 2007, 13:7254-7263.
2. Gross A., McDonnell J.M., Korsmeyer S.J. BCL-2 family members and the mitochondria in apoptosis. Genes Dev 1999, 13:1899-1911.
3. Letai A., Sorcinelli M.D., Beard C., Korsmeyer S.J. Antiapoptotic BCL-2 is required for maintenance of a model leukemia. Cancer Cell 2004, 6:241-249.
4. Srivastava R.K., Sasaki C.Y., Hardwick J.M., Longo D.L. Bcl-2-mediated drug resistance: inhibition of apoptosis by blocking nuclear factor of activated T lymphocytes (NFAT)-induced Fas ligand transcription. J. Exp. Med 1999, 190:253-265.
5. Chen L., Bourguignon L.Y. Hyaluronan-CD44 interaction promotes c-Jun signaling and miRNA21 expression leading to Bcl-2 expression and chemoresistance in breast cancer cells. Mol. Cancer 2014, 13:52.
6. O'Driscoll L., Cronin D., Kennedy S.M., Purcell R., Linehan R., Glynn S., et al. Expression and prognostic relevance of Mcl-1 in breast cancer. Anticancer Res 2004, 24:473-482.
7. Schuyer M., van der Burg M.E., Henzen-Logmans S.C., Fieret J.H., Klijn J.G., Look M.P., et al. Reduced expression of BAX is associated with poor prognosis in patients with epithelial ovarian cancer: a multifactorial analysis of TP53, p21, BAX and BCL-2. Br. J. Cancer 2001, 85:1359-1367.
8. Karakas T., Maurer U., Weidmann E., Miething C.C., Hoelzer D., Bergmann L. High expression of bcl-2 mRNA as a determinant of poor prognosis in acute myeloid leukemia. Ann. Oncol 1998, 9:159-165.
9. Wesarg E., Hoffarth S., Wiewrodt R., Kroll M., Biesterfeld S., Huber C., et al. Targeting BCL-2 family proteins to overcome drug resistance in non-small cell lung cancer. Int. J. Cancer 2007, 121:2387-2394.
10. Martin L.A., Dowsett M. BCL-2: a new therapeutic target in estrogen receptor-positive breast cancer?. Cancer Cell 2013, 24:7-9.
11. Begley J., Vo D.D., Morris L.F., Bruhn K.W., Prins R.M., Mok S., et al. Immunosensitization with a Bcl-2 small molecule inhibitor. Cancer Immunol. Immunother 2009, 58:699-708.
12. Oltersdorf T., Elmore S.W., Shoemaker A.R., Armstrong R.C., Augeri D.J., Belli B.A., et al. An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature 2005, 435:677-681.
13. Cristofanon S., Fulda S. ABT-737 promotes tBid mitochondrial accumulation to enhance TRAIL-induced apoptosis in glioblastoma cells. Cell Death Dis 2012, 3:e432.
14. Klymenko T., Brandenburg M., Morrow C., Dive C., Makin G. The novel Bcl-2 inhibitor ABT-737 is more effective in hypoxia and is able to reverse hypoxia-induced drug resistance in neuroblastoma cells. Mol. Cancer Ther 2011, 10:2373-2383.
15. Song J.H., Kandasamy K., Zemskova M., Lin Y.W., Kraft A.S. The BH3 mimetic ABT-737 induces cancer cell senescence. Cancer Res 2011, 71:506-515.
16. Bodet L., Gomez-Bougie P., Touzeau C., Dousset C., Descamps G., Maiga S., et al. ABT-737 is highly effective against molecular subgroups of multiple myeloma. Blood 2011, 118:3901-3910.
17. Huang S., Sinicrope F.A. BH3 mimetic ABT-737 potentiates TRAIL-mediated apoptotic signaling by unsequestering Bim and Bak in human pancreatic cancer cells. Cancer Res 2008, 68:2944-2951.
18. Wroblewski D., Mijatov B., Mohana-Kumaran N., Lai F., Gallagher S.J., Haass N.K., et al. The BH3-mimetic ABT-737 sensitizes human melanoma cells to apoptosis induced by selective BRAF inhibitors but does not reverse acquired resistance. Carcinogenesis 2013, 34:237-247.
19. Jain H.V., Meyer-Hermann M. The molecular basis of synergism between carboplatin and ABT-737 therapy targeting ovarian carcinomas. Cancer Res 2011, 71:705-715.
20. Touzeau C., Dousset C., Bodet L., Gomez-Bougie P., Bonnaud S., Moreau A., et al. ABT-737 induces apoptosis in mantle cell lymphoma cells with a Bcl-2 high/Mcl-1 low profile and synergizes with other antineoplastic agents. Clin. Cancer Res 2011, 17:5973-5981.
21. Meynet O., Beneteau M., Jacquin M.A., Pradelli L.A., Cornille A., Carles M., et al. Glycolysis inhibition targets Mcl-1 to restore sensitivity of lymphoma cells to ABT-737-induced apoptosis. Leukemia 2012, 26:1145-1147.
22. Stam R.W., Den Boer M.L., Schneider P., de Boer J., Hagelstein J., Valsecchi M.G., et al. Association of high-level MCL-1 expression with in vitro and in vivo prednisone resistance in MLL-rearranged infant acute lymphoblastic leukemia. Blood 2010, 115:1018-1025.
23. Kaufmann S.H., Karp J.E., Svingen P.A., Krajewski S., Burke P.J., Gore S.D., et al. Elevated expression of the apoptotic regulator Mcl-1 at the time of leukemic relapse. Blood 1998, 91:991-1000.
24. Baguley B.C. Multiple drug resistance mechanisms in cancer. Mol. Biotechnol 2010, 46:308-316.
25. Thomas S., Quinn B.A., Das S.K., Dash R., Emdad L., Dasgupta S., et al. Targeting the Bcl-2 family for cancer therapy. Expert Opin. Ther. Targets 2013, 17:61-75.
26. Martin A.P., Miller A., Emad L., Rahmani M., Walker T., Mitchell C., et al. Lapatinib resistance in HCT116 cells is mediated by elevated MCL-1 expression and decreased BAK activation and not by ERBB receptor kinase mutation. Mol. Pharmacol 2008, 74:807-822.
27. Yecies D., Carlson N.E., Deng J., Letai A. Acquired resistance to ABT-737 in lymphoma cells that up-regulate MCL-1 and BFL-1. Blood 2010, 115:3304-3313.
28. Boiani M., Daniel C., Liu X., Hogarty M.D., Marnett L.J. The stress protein BAG3 stabilizes Mcl-1 protein and promotes survival of cancer cells and resistance to antagonist ABT-737. J. Biol. Chem 2013, 288:6980-6990.
29. Lucas K.M., Mohana-Kumaran N., Lau D., Zhang X.D., Hersey P., Huang D.C., et al. Modulation of NOXA and MCL-1 as a strategy for sensitizing melanoma cells to the BH3-mimetic ABT-737. Clin. Cancer Res 2012, 18:783-795.
30. Moss R.J., Petrie C.R., Meyer R.B., Nord L.D., Willis R.C., Smith R.A., et al. Synthesis, intramolecular hydrogen bonding, and biochemical studies of clitocine, a naturally occurring exocyclic amino nucleoside. J. Med. Chem 1988, 31:786-790.
31. Fortin H., Tomasi S., Delcros J.G., Bansard J.Y., Boustie J. In vivo antitumor activity of clitocine, an exocyclic amino nucleoside isolated from Lepista inversa. ChemMedChem 2006, 1:189-196.
32. Ren G., Zhao Y.P., Yang L., Fu C.X. Anti-proliferative effect of clitocine from the mushroom Leucopaxillus giganteus on human cervical cancer HeLa cells by inducing apoptosis. Cancer Lett 2008, 262:190-200.
33. Sun J.G., Li H., Li X., Zeng X., Wu P., Fung K.P., et al. Clitocine targets Mcl-1 to induce drug-resistant human cancer cell apoptosis in vitro and tumor growth inhibition in vivo. Apoptosis 2014, 19:871-882.
34. Bolesta E., Pfannenstiel L.W., Demelash A., Lesniewski M.L., Tobin M., Schlanger S.E., et al. Inhibition of Mcl-1 promotes senescence in cancer cells: implications for preventing tumor growth and chemotherapy resistance. Mol. Cell. Biol 2012, 32:1879-1892.
35. Okumura K., Huang S., Sinicrope F.A. Induction of Noxa sensitizes human colorectal cancer cells expressing Mcl-1 to the small-molecule Bcl-2/Bcl-xL inhibitor, ABT-737. Clin. Cancer Res 2008, 14:8132-8142.
36. Yin S., Dong Y., Li J., Fan L., Wang L., Lu J., et al. Methylseleninic acid potentiates multiple types of cancer cells to ABT-737-induced apoptosis by targeting Mcl-1 and Bad. Apoptosis 2012, 17:388-399.
37. Koopman G., Reutelingsperger C.P., Kuijten G.A., Keehnen R.M., Pals S.T., van Oers M.H. Annexin V for flow cytometric detection of phosphatidylserine expression on B cells undergoing apoptosis. Blood 1994, 84:1415-1420.
38. Zhang C., Cai T.Y., Zhu H., Yang L.Q., Jiang H., Dong X.W., et al. Synergistic antitumor activity of gemcitabine and ABT-737 in vitro and in vivo through disrupting the interaction of USP9X and Mcl-1. Mol. Cancer Ther 2011, 10:1264-1275.
39. Song J.H., Kraft A.S. Pim kinase inhibitors sensitize prostate cancer cells to apoptosis triggered by Bcl-2 family inhibitor ABT-737. Cancer Res 2012, 72:294-303.
40. Fecker L.F., Geilen C.C., Tchernev G., Trefzer U., Assaf C., Kurbanov B.M., et al. Loss of proapoptotic Bcl-2-related multidomain proteins in primary melanomas is associated with poor prognosis. J. Invest. Dermatol 2006, 126:1366-1371.
41. Russo M., Spagnuolo C., Volpe S., Tedesco I., Bilotto S., Russo G.L. ABT-737 resistance in B-cells isolated from chronic lymphocytic leukemia patients and leukemia cell lines is overcome by the pleiotropic kinase inhibitor quercetin through Mcl-1 down-regulation. Biochem. Pharmacol 2013, 85:927-936.
42. Chao D.T., Korsmeyer S.J. BCL-2 family: regulators of cell death. Annu. Rev. Immunol 1998, 16:395-419.
43. Yang-Yen H.F. Mcl-1: a highly regulated cell death and survival controller. J. Biomed. Sci 2006, 13:201-204.
44. Zheng L., Yang W., Zhang C., Ding W.J., Zhu H., Lin N.M., et al. GDC-0941 sensitizes breast cancer to ABT-737 in vitro and in vivo through promoting the degradation of Mcl-1. Cancer Lett 2011, 309:27-36.
45. Doi K., Li R., Sung S.S., Wu H., Liu Y., Manieri W., et al. Discovery of marinopyrrole A (maritoclax) as a selective Mcl-1 antagonist that overcomes ABT-737 resistance by binding to and targeting Mcl-1 for proteasomal degradation. J. Biol. Chem 2012, 287:10224-10235.
46. Domina A.M., Vrana J.A., Gregory M.A., Hann S.R., Craig R.W. MCL1 is phosphorylated in the PEST region and stabilized upon ERK activation in viable cells, and at additional sites with cytotoxic okadaic acid or taxol. Oncogene 2004, 23:5301-5315.
47. De Biasio A., Vrana J.A., Zhou P., Qian L., Bieszczad C.K., Braley K.E., et al. N-terminal truncation of antiapoptotic MCL1, but not G2/M-induced phosphorylation, is associated with stabilization and abundant expression in tumor cells. J. Biol. Chem 2007, 282:23919-23936.
48. Gojo I., Zhang B., Fenton R.G. The cyclin-dependent kinase inhibitor flavopiridol induces apoptosis in multiple myeloma cells through transcriptional repression and down-regulation of Mcl-1. Clin. Cancer Res 2002, 8:3527-3538.
49. Chen S., Dai Y., Harada H., Dent P., Grant S. Mcl-1 down-regulation potentiates ABT-737 lethality by cooperatively inducing Bak activation and Bax translocation. Cancer Res 2007, 67:782-791.